Sarcosine
- Generic Name
- Sarcosine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C3H7NO2
- CAS Number
- 107-97-1
- Unique Ingredient Identifier
- Z711V88R5F
- Background
Sarcosine has been investigated for the treatment of Schizophrenia.
- Associated Conditions
- -
- Associated Therapies
- -
Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Chang-Hua Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT01047592
- Locations
- 🇨🇳
Changhua Hospital, Changhua, Taiwan
N-methylglycine (Sarcosine) Treatment for Depression
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- China Medical University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00977353
- Locations
- 🇨🇳
Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2006-05-19
- Lead Sponsor
- China Medical University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00328276
- Locations
- 🇨🇳
Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath